ORMP
Oramed Pharmaceuticals Inc
NASDAQ: ORMP · HEALTHCARE · BIOTECHNOLOGY
$4.62
+4.38% today
Updated 2026-06-04
Market cap
$149.38M
P/E ratio
1.39
P/S ratio
86.55x
EPS (TTM)
$2.62
Dividend yield
—
52W range
$2 – $5
Volume
0.2M
WallStSmart proprietary scores
45
out of 100
Grade: C
Sell
Investment rating
4.7
Growth
C9.0
Quality
A+5.0
Profitability
C+6.7
Valuation
B4/9
Piotroski F-Score
Moderate
4.8
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$6.25
+35.28%
12-Month target
$4.14
-10.39%
Intrinsic (DCF)
—
Margin of safety
—
Price chart
Stock snapshot
Strengths
+ Altman Z 4.78 — safe zone
+ ROE 58.20% — strong efficiency
+ Debt/equity 0.00x — low leverage
Risks
- Thin margins at 0.00%
- Negative free cash flow $-2.92M
- Revenue declining -100.00% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $2.70M | $1.34M | $0.00 | $2.00M | $0.00 |
| Net income | $-37.76M | $5.53M | $-19.10M | $64.05M | $38.31M |
| EPS | — | — | — | — | $2.62 |
| Free cash flow | $-29.20M | $-10.55M | $-8.43M | $-11.08M | $-2.92M |
| Profit margin | -1,397.11% | 412.31% | — | 3,202.50% | — |
Peer comparison
Smart narrative
Oramed Pharmaceuticals Inc trades at $4.62. representing a P/E of 1.39x trailing earnings. Our Smart Value Score of 45/100 indicates the stock is fair. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of 4.78, it sits in the safe zone.
Frequently asked questions
What is Oramed Pharmaceuticals Inc's stock price?
Oramed Pharmaceuticals Inc (ORMP) trades at $4.62, on a P/E of 1.4x and a P/S of 86.6x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Oramed Pharmaceuticals Inc overvalued?
Oramed Pharmaceuticals Inc carries a Smart Value Score of 45/100 (Grade C), which we rate Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Oramed Pharmaceuticals Inc (ORMP)?
The 12-month analyst consensus target is $6.25, about 35.3% above the current $4.62. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Oramed Pharmaceuticals Inc's Altman Z-Score is 4.78, which places it in the safe zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio86.55x
ROE58.20%
Beta1.24
50D MA$3.90
200D MA$3.11
Shares out0.04B
Float0.03B
Short ratio—
Avg volume0.2M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—